Table 1 Summary of treatments and doses used in gonad cultures

DMSO (vehicle control)

Equal to DMSO in drug treatments (≥ 1/5000)

NA

NA

Thermo-Fisher, D12345

BGJ398/ Infigratinib (FGFRi)

125, 250, 500, 1000 and 2500 nM

IC50 – FGFR1–3: 0.9–1.4 nM, FGFR4: 60 nM

Phase II, NCT02150967

SelleckChem, S2183

[31]

PD0325901/ Mirdametinib (MEKi)

125, 250, 500 and 1000 nM

IC50 – MEK: 0.33 nM

Phase II, NCT03962543

SelleckChem, S1036 or MedChem Express, HY-10254

[32]

PH-797804 (p38i)

500 nM

IC50 – p38α: 26 nM; p38β 102 nM

Phase II, NCT00559910

MedChem Express, HY-10403

[33]

GSK1059615 (PI3Ki)

500 nM

IC50 – PI3Kα/ β/δ/γ: 0.4–5 nM, mTOR: 12 nM

Phase I, NCT00695448

MedChem Express, HY-12036

Recombinant mouse FGF9

50 ng/mL

FGFR1-3

NA

R&D systems, 7399-F9-025

[20]

AZD4547 (second FGFR inhibitor)

125, 250 and 500 nM

IC50 – FGFR1-3: 0.2–2.5 nM; FGFR4: 165 nM; VEGFR2: 24 nM

Phase II, NCT02465060

SelleckChem, S2801

[34]

SU5402 (third FGFR inhibitor)

5000 nM

IC50 VEGFR: 20 nM; FGFR1: 30 nM

N/A

MedChem Express, HY-10407

[35]

Ralimetinib dimesylate/ LY2228820 (second p38 inhibitor)

500 nM

IC50 – p38α: 5.3 nM; p38β: 5.3 nM

Phase I, NCT01663857

MedChem Express, HY-13241

[36]

PF-04691502 (second PI3K inhibitor)

500 nM

IC50 – PI3Kα/ β/δ/γ: 1.6–2.1 nM; mTOR: 16 nM

Phase II, NCT01420081

MedChem Express, HY-15177

[37]